Vertex
By therapeutic area
| Therapeutic area | Premium | Deals |
|---|---|---|
| oncology | ×1.19 | 15 |
By stage at signing
| Phase | Premium | Deals |
|---|---|---|
| approved | ×1.40 | 5 |
| phase 3 | ×0.82 | 3 |
| discovery | ×0.91 | 3 |
Strategy profile
Based on 4 disclosed transactions, Vertex concentrates its licensing activity in Oncology, Neurology. Vertex pays a 1.19x premium over market median, with the strongest premiums in Oncology (1.19x). Their most common deal structure is Co Development, with an average disclosed value of $469M. Most recent activity: 2025.
Premium by therapeutic area
How Vertex pays relative to peer medians in each TA
Pipeline coverage & gaps
Vertex has disclosed activity in 1 of 12 tracked therapeutic areas. Gaps may represent whitespace opportunities for licensors.
Deal type breakdown
How this buyer structures its transactions
| Deal type | Count | Avg upfront | Avg total value |
|---|---|---|---|
| Co DevelopmentPrimary | 2 | $39M | $422M |
| Option | 1 | $115M | $812M |
| Collaboration | 1 | $15M | $217M |
Recent disclosed deals
| Year | Asset | Licensor | Indication | Phase | Upfront | Total |
|---|---|---|---|---|---|---|
| 2025 | LIV-1 | Bicycle Therapeutics | Breast (HR+) | discovery | $32M | $328M |
| 2024 | PD-1 | Forma Therapeutics | GBM | preclinical | $45M | $516M |
| 2022 | TGF-β-101 | CRISPR Therapeutics | Breast (HER2+) | phase_2 | $115M | $812M |
| 2020 | C9orf72 | Athira Pharma | OCD | discovery | $15M | $217M |
How this is computed
For each Vertex deal we find the median total deal value of comparable transactions (same therapeutic area + phase, falling back to TA-only with ≥3 peers). The buyer’s deal divided by the peer median is the per-deal premium. We trim outliers, take the trimmed mean, and clamp to [0.7×, 1.5×] to reject data errors. Confidence scales with sample size.
Trimmed mean of 15 disclosed deal premiums vs. peer medians. Raw premium 1.191, clamped to [0.7, 1.5].